Michael R. Knowles, M.D.
Dr. Michael R. Knowles is a Professor of Pulmonary and Critical Care medicine at the University of North Carolina. He has over three decades of clinical research experience that spans across the disciplines of biology, physiology, and design of clinical trials in both the academic and private sectors. He is currently the head of two large multicenter studies: 1) Genetic Modifiers of Disease phenotype (severity) in cystic fibrosis lung and liver disease, which also includes a recently formed International Consortium doing a whole genome scan; and 2) a Consortium with 8 sites in North America to study rare genetic disorders of mucociliary clearance. He received his B.A. and M.D. from the University of North Carolina at Chapel Hill, Chapel Hill, NC, completed his Residency in Internal Medicine at Duke University, Durham, NC, and finished his Fellowship in pulmonary diseases at the University of North Carolina at Chapel Hill. Dr. Knowles has authored over 100 papers over the course of his career.
George Kunos, M.D., Ph.D.
Dr. George Kunos is the Scientific Director at the National Institute on Alcohol Abuse and Alcoholism (NIAAA), a component of the National Institutes of Health (NIH) and Chief of the Laboratory of Physiologic Studies. Dr. Kunos' current research is focused on the biology of endocannabinoids, particularly their role in the regulation of metabolism, cardiovascular functions and appetitive behavior, including alcohol drinking behavior. Prior to joining the NIH as Scientific Director in 2000, Dr. Kunos served as Professor and Chair of the Department of Pharmacology & Toxicology at Virginia Commonwealth University in Richmond, VA. He previously held the role as Professor of Pharmacology and Medicine at McGill University.
Dr. Kunos received his M.D. from Semmelweis University in Budapest, Hungary and a Ph.D. in pharmacology from McGill University in Montreal, Canada. He is an elected Fellow of the American Heart Association and a foreign member of the Hungarian Academy of Sciences.
Charles N. Serhan, Ph.D., DSc
Dr. Charles N. Serhan is the first Endowed Distinguished Scientist at Brigham and Women's Hospital (BWH) and since 1995 has served as Director of the Center for Experimental Therapeutics and Reperfusion Injury (CET&RI) at BWH. He is a full Professor of Anesthesia at Harvard Medical School, is affiliated with its Department of Biological Chemistry and Molecular Pharmacology, and is also the Simon Gelman Professor of Anesthesia, Perioperative and Pain Medicine (Biochemistry & Molecular Pharmacology) at Harvard Medical School and Professor of Oral Medicine, Infection and Immunity at Harvard School of Dental Medicine. Dr. Serhan is a leading authority in inflammatory resolution and was the first to identify the role of anti-inflammatory cellular mediators such as resolvins and lipoxins in the pro-inflammatory pathway. He serves as the Director and Principal Investigator of the Serhan Laboratory at CET&RI and as the program director of a federally supported National Institutes of Health Program Project grant on the Resolution Mechanisms in Acute Inflammation: Resolution Pharmacology. He is also Principal Investigator on the NIH research grant entitled, Blood Cell Lipoxygenase Products: Formation and Action, funded since 1987, and is honored with a MERIT Award and has authored over 400 papers.
Dr. Serhan received his Bachelor's degree in Biochemistry from Stony Brook University New York and his doctorate in Experimental Pathology and Medical Sciences from New York University School of Medicine. He completed his post-doctoral training in Physiological Chemistry at the Karolinska Institute Medical University in Sweden with Professor Bengt Samuelsson, the 1982 Nobel Laureate in Medicine, and later received an honorary degree from Harvard University.